Abstract
We retrospectively analyzed the prognostic significance of mixed chimerism and associated clinical parameters in 80 patients following unmanipulated allogenic stem cell transplantation. Chimerism studies were performed on marrow aspirates using fluorescent in situ hybridization and variable number tandem repeats techniques at day +30, day +90 and +12 months. The median overall survival (OS) was 24 months (range, 1–56 months). Mixed chimerism was found in 23, 28 and 14% of patients at day +30 (1 month), +90 (3 months), and +12 months, respectively. Day +30 chimerism studies failed to provide any prognostic information. Day +90 mixed chimeras (MC) had significantly higher relapse rates compared to day +90 complete chimeras (CC) at 6 months (P=0.03) and 18 months when compared to MC (P=0.03) following transplant. The median OS in day +90 MC and day+90 CC were, respectively (95% CI, 2–35 months), compared to 47 months (95% CI, 20–74 months) (P=0.02). In conclusion, chimerism studies on day +30 could be reserved for patients who fail to demonstrate engraftment. Day +90 MC had higher relapse rates and lower OS, and therefore may be considered for novel therapies and future studies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ugozzoli L, Yam P, Petz LD, Ferrara GB, Champlin RE, Forman SJ et al. Amplification by the polymerase chain reaction of hypervariable regions of the human genome for evaluation of chimerism after bone marrow transplantation. Blood 1991; 77: 1607–1615.
van Dekken H, Hangenbeek A, Bauman JG . Detection of host cells following sex-mismatched bone marrow transplantation by fluorescent in situ hybridization with a Y-chromosome specific probe. Leukemia 1989; 3: 724–728.
Roth MS, Antin JH, Bingham EL, Ginsburg D . Use of polymerase chain reaction detected sequence polymorphisms to document engraftment following allogenic bone marrow transplantation. Transplantation 1990; 49: 714–720.
Chalmers EA, Sproul AM, Mills KI, Gibson BE, Burnett AK . Use of polymerase chain reaction to monitor engraftment following allogenic bone marrow transplantation. Bone Marrow Transplant 1990; 6: 399–403.
Browne PV, Lawler M, O'Riordan J, Humphries P, McCann SR . Early detection of leukemic relapse after bone marrow transplantation using the polymerase chain reaction. Bone Marrow Transplant 1991; 7: 167–169.
Lawler M, Humphries P, McCann SR . Evaluation of mixed chimerism by in vitro amplification of dinucleotide repeat sequences using the polymerase chain reaction. Blood 1991; 77: 2504–2514.
Ortega M, Escudero T, Caballin MR, Olive T, Ortega JJ, Coll MD . Follow up of chimerism in children with hematological diseases after allogenic hematopoietic progenitor cell transplants. Bone Marrow Transplant 1999; 24: 81–87.
van Leeuwen JE, van Tol MJ, Joosten AM, Wijnen JT, Verweij PJ, Khan PM et al. Persistence of host-type hematopoiesis after allogenic bone marrow transplantation for leukemia is significantly related to the recipient's age and/or the conditioning regimen, but is not associated with an increased risk of relapse. Blood 1994; 83: 3059–3067.
Ugozzoli L, Yam P, Petz LD, Ferrara GB, Champlin RE, Forman SJ et al. Amplification by the polymerase chain reaction of hypervariable regions of the human genome for evaluation of chimerism after bone marrow transplantation. Blood 1991; 77: 1607–1615.
Boerwinkle E, Xiong W, fourest E, Chan L . Rapid typing of tandemly repeated hypervariable loci by the polymerase chain reaction: Application to the apolipoprotein B 3′ hypervariable region. Genetics 1989; 86: 212–216.
Hill RS, Petersen FB, Storb R, Appelbaum FR, Doney K, Dahlberg S et al. Mixed hematologic chimerism after allogenic marrow transplantation for severe aplastic anemia is associated with higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease. Blood 1986; 67: 811–816.
Petz LD, Yam P, Wallace RB, Stock AD, de Lange G, Knowlton RG et al. Mixed hematopoietic chimerism following bone marrow transplantation for hematologic malignancies. Blood 1987; 70: 1331–1337.
Bader P, Holle W, Klingebiel T, Handgretinger R, Benda N, Schlegel PG et al. Mixed hematopoietic chimerism after allogenic bone marrow transplantation: the impact of quantitative PCR analysis for prediction of relapse and graft rejection in children. Bone Marrow Transplant 1999; 19: 697–702.
Bertheas MF, Lafage M, Levy P, Blaise D, Stoppa AM, Viens P et al. Influence of mixed chimerism on the results of allogenic bone marrow transplantation for leukemia. Blood 1991; 78: 3103–3106.
Offit K, Burns JP, Cunningham I, Jhanwar SC, Black P, Kernan NA et al. Cytogenetic analysis of chimerism and leukemia relapse in chronic myelogenous leukemia patients after T-cell depleted bone marrow transplantation. Blood 1990; 75: 1346–1355.
Roux E, Helg C, Chapuis B, Jeannet M, Roosnek E . Evolution of mixed chimerism after allogenic bone marrow transplantation as determined on granulocytes and mononuclear cells by the polymerase chain reaction. Blood 1992; 79: 2775–2783.
Bretagne S, Vidaud M, Kuentz M, Cordonnier C, Henni T, Vinci G et al. Mixed blood chimerism in T cell depleted bone marrow transplant recipients: evaluation using DNA polymorphisms. Blood 1987; 70: 1692–1695.
McSweeney PA, Storb R . Mixed chimerism: preclinical studies and clinical applications. Biol Blood Marrow Transplant 1999; 5: 192–203.
Schattenberg A, Bar B, Smeets D, Geurts van Kessel A, De Witte T . Comparision of chimerism of red cells with that of granulocytes, T-lymphocytes and bone marrow cells in recipients of bone marrow grafts depleted of lymphocytes using counter flow centrifugation. Leukemia Lymphoma 1991; 5: 171–177.
Suttorp M, Schmitz N, Dreger P, Schaub J, Loffler H . Monitoring of chimerism after allogenic bone marrow transplantation with unmanipulated marrow by use of DNA polymorphisms. Leukemia 1993; 7: 679–687.
Champlin R, Mc Glave P . Allogenic bone marrow transplantation for chronic myelogenous leukemia. In: Forman S, Blume K, Thomas E (eds) Bone Marrow Transplantation. Boston, MA: Blackwell Scientific, 1994, p 595.
Long G, Blume K . Allogenic bone marrow transplantation for acute myeloid leukemia. In: Forman S, Blume K, Thomas E (eds) Bone Marrow Transplantation. Boston, MA: Blackwell Scienticfic, 1994, p 607.
Chao N, Forman S . Allogenic bone marrow transplantation for acute lymphoblastic leukemia. In: Forman S, Blume K, Thomas E (eds) Bone Marrow Transplantation. Boston, MA: Blackwell Scientific, 1994, p 618.
Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806–814.
Bader P, Beck J, Frey A, Schlegel PG, Hebarth H, Handgretinger R et al. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogenic BMT. Bone Marrow Transplant 1998; 21: 487–495.
Molloy K, Goulden N, Lawler M, Cornish J, Oakhill A, Pamphilon D et al. Patterns of hematopoietic chimerism following bone marrow transplantation for childhood acute lymphoblastic leukemia from volunteer unrelated donors. Blood 1996; 87: 3027–3031.
Roman J, Martin C, Torres A, Garcia A, Andres P, Garcia MJ et al. Importance of mixed chimerism to predict relapse in persistently bcr/abl positive long term survivors after allogenic bone marrow transplantation for chronic myeloid leukemia. Leukemia Lymphoma 1998; 28: 541–550.
Radich JP, Gehly G, Gooley T, Bryant E, Clift RA, Collins S et al. Polymerasechain reaction detection of BCR-ABL fusion transcript after allogenic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995; 85: 2632–2638.
Socie G, Lawler M, Gluckman E, McCann SR, Brison O . Studies on hematopoietic chimerism following allogenic bone marrow transplantation in the molecular biology era. Leukemia Res 1995; 19: 497–504.
Dubovsky J, Daxberger H, Fritsch G, Printz D, Peters C, Matthes S et al. Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders; implications for timely detection of engraftment, graft failure and rejection. Leukemia 1999; 13: 2060–2069.
Frassoni F, Strada P, Sessarego M, Miceli S, Corvo R, Scarpati D et al. Mixed chimerism after allogenic marrow transplantation for leukemia: correlation with dose of total body irradiation and graft-versus-host disease. Bone Marrow Transplant 1990; 5: 235–240.
Chalmers EA, Sproul AM, Mills KI, Stewart J, McNee S, Jones R et al. Effect of radiation dose on the development of mixed haemopoietic chimerism following T-cell depleted allogenic bone marrow transplantation. Bone Marrow Transplant 1992; 10: 425–430.
Mackinnon S, Barnett L, Bourhis JH, Black P, Heller G, O'Reilly RJ . Myeloid and lymphoid chimerism after T-cell depleted bone marrow transplantation: evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA. Blood 1992; 80: 3235–3241.
Bar BM, Schattenberg A, De Man AJ, Hoogenhout MJ, Boezeman J, de Witte T . Influence of the conditioning regimen on erythrocyte chimerism, graft-versus-host disease and relapse after allogenic transplantation with lymphocyte depleted marrow. Bone Marrow Transplant 1992; 10: 45–52.
Acknowledgements
We thank Ronald L Thomas for statistical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lamba, R., Abella, E., Kukuruga, D. et al. Mixed hematopoietic chimerism at day 90 following allogenic myeloablative stem cell transplantation is a predictor of relapse and survival. Leukemia 18, 1681–1686 (2004). https://doi.org/10.1038/sj.leu.2403468
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403468
Keywords
This article is cited by
-
Early recipient chimerism testing in the T- and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation
Leukemia (2012)
-
Comparison of donor chimerism following myeloablative and nonmyeloablative allogeneic hematopoietic SCT
Bone Marrow Transplantation (2011)
-
Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity
Bone Marrow Transplantation (2011)
-
Assessing quantitative chimerism longitudinally: technical considerations, clinical applications and routine feasibility
Bone Marrow Transplantation (2007)
-
Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma
Bone Marrow Transplantation (2007)